DK1127137T4 - LPS med reduceret toksicitet fra genetisk modificerede gram-negative bakterier - Google Patents

LPS med reduceret toksicitet fra genetisk modificerede gram-negative bakterier

Info

Publication number
DK1127137T4
DK1127137T4 DK98954832.6T DK98954832T DK1127137T4 DK 1127137 T4 DK1127137 T4 DK 1127137T4 DK 98954832 T DK98954832 T DK 98954832T DK 1127137 T4 DK1127137 T4 DK 1127137T4
Authority
DK
Denmark
Prior art keywords
lps
molecule
acyl chains
recombinant
glucosamine
Prior art date
Application number
DK98954832.6T
Other languages
English (en)
Other versions
DK1127137T3 (da
Inventor
Der Ley Peter Andre Van
Hendrik Jan Hamstra
Liana Juliana Josephine Margriet Steeghs
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19866463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1127137(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Application granted granted Critical
Publication of DK1127137T3 publication Critical patent/DK1127137T3/da
Publication of DK1127137T4 publication Critical patent/DK1127137T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK98954832.6T 1998-11-03 1998-11-03 LPS med reduceret toksicitet fra genetisk modificerede gram-negative bakterier DK1127137T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL1998/000633 WO2000026384A1 (en) 1998-11-03 1998-11-03 Lps with reduced toxicity from genetically modified gram negative bacteria

Publications (2)

Publication Number Publication Date
DK1127137T3 DK1127137T3 (da) 2008-01-02
DK1127137T4 true DK1127137T4 (da) 2014-02-10

Family

ID=19866463

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98954832.6T DK1127137T4 (da) 1998-11-03 1998-11-03 LPS med reduceret toksicitet fra genetisk modificerede gram-negative bakterier

Country Status (12)

Country Link
US (1) US6482807B1 (da)
EP (2) EP1127137B2 (da)
JP (1) JP3595264B2 (da)
AT (1) ATE373714T1 (da)
AU (1) AU762369B2 (da)
CA (1) CA2348928C (da)
DE (1) DE69838460T3 (da)
DK (1) DK1127137T4 (da)
ES (1) ES2294821T5 (da)
NZ (1) NZ511438A (da)
PT (1) PT1127137E (da)
WO (1) WO2000026384A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
DK1284740T3 (da) * 2000-05-19 2008-08-04 Corixa Corp Profylaktisk og terapeutisk behandling af infektiöse sygdomme, autoimmunsygdomme og allergiske sygdomme med monosaccharidbaserede forbindelser
EP1322328B1 (en) 2000-07-27 2014-08-20 Children's Hospital & Research Center at Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
AU2002223970A1 (en) * 2000-10-06 2002-04-15 H. Henrich Paradies Kyberdrug as autovaccines with immune-regulating effects
EP1372707A1 (en) * 2001-04-06 2004-01-02 Institut Pasteur Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of vibrio cholerae 0139 bound to tetanus toxoid
EP1961427A3 (en) 2002-08-02 2009-11-04 GlaxoSmithKline Biologicals S.A. Neisserial vaccine compositions comprising a combination of antigens
WO2005030122A2 (en) * 2003-08-13 2005-04-07 Chiron Corporation Inactivated host cell delivery of polynucleotides encoding immunogens
PL1748791T3 (pl) 2004-05-11 2010-08-31 De Staat Der Nederlanden Vert Door De Mini Van Vws LOS IgtB Neisseria Meningitidis jako adjuvant
BRPI0519923A8 (pt) * 2004-12-17 2018-01-23 De Staat Der Nederlanden Vertegenwoordigd Door De Mini Van Vws polipeptídeo, seqüência de dna, vetor de dna, anticorpo, bactéria, método para produzir lps parcialmente 3-0-desacilado, composição, usos da bactéria, e de lps de bordetella isolado compreendendo lps pelo menos parcialmente 3-0-desacilado, vacina, e, método in vitro para a desacilação de lps gram-negativo ou de composições compreendendo lps gram-negativo, e, para induzir uma resposta imune contra bordetella.
JP4993750B2 (ja) 2005-01-27 2012-08-08 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のための、ｇｎａ１８７０を基にした小胞ワクチン
WO2007144316A2 (en) 2006-06-12 2007-12-21 Glaxosmithkline Biologicals Sa Vaccine
NZ579940A (en) * 2007-03-26 2012-03-30 Nederlanden Staat Improved vaccines against bordetella pertussis based on lps glycosyltransferase mutants
US20090035328A1 (en) * 2007-08-02 2009-02-05 Dan Granoff fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS
EP2200642B1 (en) 2007-10-19 2012-04-18 Novartis AG Meningococcal vaccine formulations
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
CA2761916A1 (fr) 2009-05-14 2010-11-18 Sanofi Pasteur Procede pour adjuver le lipopolysaccharide (lps) des bacteries a gram-negatif
AU2010247254A1 (en) 2009-05-14 2012-01-12 Sanofi Pasteur Menigococcus vaccine containing lipooligosaccharide (LOS) from modified strains of L6 immunotype Neisseria meningitidis
CA2772103A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
CN102869378A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
CA2793510A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
US20130066064A1 (en) * 2010-05-20 2013-03-14 Glaxosmithkline Biologicals S.A, Novel process
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
CA2840096C (en) 2011-07-07 2021-07-06 Bas VAN DE WATERBEEMD A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
RU2014135522A (ru) 2012-02-02 2016-03-27 Новартис Аг Промоторы для увеличенной экспрессии белка у менингококка
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
BR112015018877A2 (pt) 2013-02-07 2017-08-22 Externautics Spa Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
US20160120967A1 (en) 2013-06-04 2016-05-05 Petr Gennadievich Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
AU2016206965B2 (en) 2015-01-12 2021-03-04 Children's Medical Center Corporation Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
BR112018015237A2 (pt) * 2016-01-28 2018-12-26 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport lps de neisseria hexa-acilado modificado
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
EP4117790A1 (en) * 2020-03-13 2023-01-18 Hephaistos-Pharma Detoxified lipopolysaccharides (lps), naturally non-toxic lps, and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria

Also Published As

Publication number Publication date
ATE373714T1 (de) 2007-10-15
ES2294821T3 (es) 2008-04-01
ES2294821T5 (es) 2014-03-05
AU1178299A (en) 2000-05-22
EP1870468A3 (en) 2010-01-13
DE69838460T3 (de) 2014-04-30
EP1127137B2 (en) 2013-12-25
JP2002528558A (ja) 2002-09-03
DK1127137T3 (da) 2008-01-02
JP3595264B2 (ja) 2004-12-02
AU762369B2 (en) 2003-06-26
US6482807B1 (en) 2002-11-19
CA2348928A1 (en) 2000-05-11
PT1127137E (pt) 2007-12-28
DE69838460D1 (de) 2007-10-31
WO2000026384A1 (en) 2000-05-11
EP1870468A2 (en) 2007-12-26
DE69838460T2 (de) 2008-06-12
EP1127137B1 (en) 2007-09-19
EP1127137A1 (en) 2001-08-29
NZ511438A (en) 2003-03-28
CA2348928C (en) 2010-01-26

Similar Documents

Publication Publication Date Title
DK1127137T4 (da) LPS med reduceret toksicitet fra genetisk modificerede gram-negative bakterier
PT618190E (pt) 9-¬glicil substituido)amido|-6-(substituido)-5-hidroxi-6-desoxitetraciclinas
ITMI930366A0 (it) Addittivi superfluidificanti ad elevata conservazione della lavorabilita'
LV12516A (en) Inhibitors of factor xawith a neutral p1 specifity group
NO932869D0 (no) 7-(substituerte)-9-((substituerte glycyl)amido)-6-demetyl-6-deoksytetracykliner
PT1123276E (pt) N-(2-aril-propionil)-sulfonamidas e preparacoes farmaceuticas que as contem
FI933567A0 (fi) Nya 7-(substituerad)-8-(substituerad)-9-(substituerad amino)-6-demetyl-6-deoxitetracykliner
TW269678B (da)
FI932104A0 (fi) Nya 4-arylpiperaziner och 4-arylpiperidiner
FI933564A0 (fi) Nya 7-(substituerad)-8-(substituerad)-9-((substituerad)glycyl)amido)-6-demetyl-6-deoxitetracykliner
MX9700557A (es) Dihidrobenzofuranos.
FI951468A (fi) Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
DE69221174D1 (de) Anordnung für Feldemissions-Mikrokathoden
DE69902526D1 (de) Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate
CY1104996T1 (el) 9α-αζαλιδια εχοντα αντιβακτηριακην δρασιν
ATE143369T1 (de) Überbrückte, cyclische ketale
ATE223235T1 (de) Chitosan induzierte verstärkung
ATE75752T1 (de) Antibiotikum.
FI931079A (fi) Mikrobmotverkande karbapenemderivat, deras framstaellning och terapeutiska anvaendning
DK0888379T3 (da) Forbindelser tilhørende amidinium-familien, farmaceutiske præparater indeholdende disse forbindelser og anvendelsen deraf
ATE361931T1 (de) N1 modifizierte glycopeptide
ATE140460T1 (de) Echinocandin-b-derivat
BR0013328A (pt) Fosfato de ester à base de adjuvantes de surfactante e suas composições
PL324884A1 (en) Application of prostane derivatives and their compositions with antibiotics in treating bacterial infections
BR9106596A (pt) Processo para o tratamento ou profilaxia de uma infeccao associada com retrovirus,uso,composicao farmaceutica para o tratamento ou profilaxia de uma infeccao associada com retrovirus,e,composto